Clinical Trials on PD-1 Antibody

Total 6016 results

Sichuan Cancer Hospital and Research Institute

Active, not recruiting

PD-1 Inhibitors Plus Chemoradiotherapy for Metastatic Nasopharyngeal Carcinoma: an Open-label Single-arm, Phase II Trial

Nasopharyngeal Carcinoma | Chemoradiotherapy | PD-1 Inhibitors

China
Sun Yat-sen University
First Affiliated Hospital, Sun Yat-Sen University; Nanfang Hospital of Southern... and other collaborators

Recruiting

Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma | Surgery | PD-1

China
Ottawa Hospital Research Institute

Not yet recruiting

Switched Memory B-cells as a Marker for Humoral Immune System Recovery in Patients With Secondary Antibody Deficiency Due to Hematological Malignancies (SAD)

Secondary Antibody Deficiency
University Hospital, Bordeaux

Recruiting

Quantitative Parameters of HLA-DQ Antibodies in Lung Transplantation (AFFIHLA-P)

Lung Transplantation | Antibody Mediated Rejection | Chronic Lung Allograft Dysfunction

France
UMC Utrecht

Completed

Early Detection of Primary Antibody Deficiencies in Primary Care Facilities by an Algorithm Driven Selection of Serologic Testing in Individuals at Risk. (GP-PAD II)

Primary Antibody Deficiencies

Netherlands
Assistance Publique - Hôpitaux de Paris
Bristol-Myers Squibb

Completed

Belatacept (Nulojix) in Renal Transplant Recipient With Mild Immunologic Risk Factor: a Pilot Prospective Study. (BELACOR)

Renal Transplant | Acute Antibody Mediated Rejection | Mild Immunologic Risk Factor

France
Guangxi Medical University
Wuzhou Red Cross Hospital; Wuhan Union Hospital, China; Yunnan Cancer Hospital; Hainan People's Hospital and other collaborators

Not yet recruiting

PD-1 Inhibitor Plus GP as Neoadjuvant Therapy for Locoregionally Advanced Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma | Neoadjuvant Therapy | PD-1 Inhibitor
Tang-Du Hospital

Recruiting

Neoadjuvant Therapy for Stage II-IVA Resectable Esophageal Squamous Cell

Chemotherapy | Esophageal Squamous Cell Carcinoma | PD-1 Inhibitor | Neoadjuvent

China
Yonsei University
Merck KGaA, Darmstadt, Germany

Active, not recruiting

K-Basket, Avelumab, Biomarker-driven, Advanced Solid Tumor

PD-L1 Positive Mutation Tumor | EBV Positive Mutation Tumor | MSI-H Mutation Tumor | POLE/POLD1 Mutation Tumor

Korea, Republic of
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Neoadjuvant Tirellizumab Combined With Chemotherapy for Early Oral Squamous Cell Carcinoma(HNC-SYSU-004)

Oral Cancer | PD-1

China
Assistance Publique - Hôpitaux de Paris
Institut Pasteur

Recruiting

Repertoire and Properties of Anti-drug Antibodies Involved in Immediate Hypersensitivity in the Operating Room (MEDIREP)

Hypersensitivity, Immediate | Peri-operative Injury | Antibody Hypersensitivity | Antibiotic Allergy

France
Guangzhou First People's Hospital
LanZhou University; Sun Yat-sen University; The Third Affiliated Hospital of... and other collaborators

Completed

HPA Antibodies and the Distribution of Antigen and Antibodies

Blood Disease | Antibody-mediated Rejection | Platelet Refractoriness

China
Amgen

Recruiting

A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis

Antineutrophil Cytoplasmic Antibody-associated Vasculitis

United States
Sun Yat-sen University
Wuzhou Red Cross Hospital; Fifth Affiliated Hospital, Sun Yat-Sen University; Affiliated Cancer Hospital & Institute of Guangzhou Medical University and other collaborators

Recruiting

Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma

Nasopharyngeal Cancer | Chemotherapy | Radiotherapy | PD-1 Therapy

China
IRCCS San Raffaele Roma

Completed

Progression of Striatal and Extrastriatal Degeneration in PD and PSP Patients (PARKONTHEWAY)

Parkinson Disease (PD) | Paralysis; Supranuclear

Italy
Staidson (Beijing) Biopharmaceuticals Co., Ltd

Completed

The Safety and Tolerability of STSA-1002 Following Subcutaneous Injection in Healthy Subjects

Antineutrophil Cytoplasmic Antibody Associated Vasculitis

United States
Amgen

Completed

A Study in Healthy Volunteers to Evaluate the Pharmacokinetic Food Effect and Cardiac Safety of CCX168

Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis

United States
PATH

Completed

Coadministration of Measles-rubella and Rotavirus Vaccines

Measles Antibody Seroconversion | Rubella Antibody Seroconversion | Rotavirus Geometric Mean Titer (GMT) | Rotavirus Immunoglobulin A (IgA) Seropositivity

Bangladesh
Medical University of Graz

Terminated

Detection and Characterization of Anti-SARS-CoV-2 Salivary Antibodies After COVID-19 Booster Vaccines (CoVVacBoost)

Anti-SARS-CoV-2 Antibody Response

Austria
Chinese PLA General Hospital

Unknown

Treatment of Chemotherapy Refractory Human Epidermalgrowth Factor Receptor-2( HER-2) Positive Advanced Solid Tumors (CART-HER-2)

Advanced HER-2 Positive Solid Tumors | Chemotherapy Refactory | HER-2 Antibody Inhibitor Therapy Refactory

China
Sun Yat-sen University
Wuzhou Red Cross Hospital; Fifth Affiliated Hospital, Sun Yat-Sen University; Affiliated Cancer Hospital & Institute of Guangzhou Medical University and other collaborators

Recruiting

Toripalimab Plus Concurrent Chemo-radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma | Chemotherapy | Radiotherapy | PD-1 Treatment

China
Amgen

Completed

A Study to Assess the Mass Balance Recovery (Absorption, Distribution, Metabolism and Excretion) of [14C]CCX168 in Healthy Participants

Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis

United States
Amgen

Completed

A Study of CCX168 in Japanese and Caucasian Healthy Adult Males

Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis

Japan
Institute of Hematology & Blood Diseases Hospital

Not yet recruiting

Humanized Anti-CD25 Antibody for Prophylaxis of aGVHD in Elderly Underwent HID-HSCT

The Effecacy and Safety of Humanized CD25 Antibody in aGVHD Prophylaxis Among Elderly Patients After HID-HSCT
Merck Medication Familiale
BioFortis

Completed

Effect of a Mixture of Probiotics on the Antigen Specific Antibody Response in a Influenza Vaccination Model of Healthy Adults (PROBIMMUNE)

Enhancement of Protective Antibody Response After Probiotic Consumption

France
Shanghai Zhongshan Hospital

Recruiting

PD-L1 Antibody Combined With CTLA-4 Antibody for Patients With Advanced Intrahepatic Cholangiocarcinoma Who Progressed After Standard Treatment

Cholangiocarcinoma, Intrahepatic | PD-L1 | CTLA4

China
The First Affiliated Hospital of Zhengzhou University

Not yet recruiting

IBI110 Combined With Sintilimab in Second-line Advanced or Metastatic Esophageal Squamous Cell Carcinoma(ESCC)

Esophageal Squamous Cell Carcinoma (ESCC) | PD-1 Inhibitors

China
University of South Florida
Merck Sharp & Dohme LLC

Terminated

Assessment of Immunogenicity of Zostavax® in Patients With Antibody Deficiency 60 Years of Age and Older

X-linked Agammaglobulinemia | Specific Antibody Deficiency | Common Variable Immune Deficiency

United States
Hospital Universitario Pedro Ernesto

Completed

CI(R)CA : Coumadin Interaction With Rofecoxib, Celecoxib and Acetaminophen (CI(R)CA)

Antiphospholipid Antibody Syndrome
Centre Hospitalier Universitaire de Nīmes

Completed

Obstetric Antiphospholipid Antibody Syndrome : Contribution of the Evaluation of ADAMTS13 Made at the Diagnosis of Pregnancy on Evaluation the Risk of Pre-eclampsia (NOH-ADAMTS)

Antiphospholipid Antibody Syndrome in Pregnancy

France
Mayo Clinic

Enrolling by invitation

Diazepam Trial in GAD65 Associated Epilepsy

GAD 65 Antibody-associated Epilepsy

United States
Mitsubishi Tanabe Pharma Corporation

Recruiting

An Exploratory Study of MT-2990 in Patients With AAV

Antineutrophil Cytoplasmic Antibody (ANCA) -Associated Vasculitis (AAV)

Japan
Johns Hopkins University

Completed

Eculizumab to Enable Renal Transplantation in Patients With History of Catastrophic Antiphospholipid Antibody Syndrome

End Stage Renal Disease | Antiphospholipid Antibody Syndrome

United States
Lei Li

Recruiting

PD-1 Antibody and Radiotherapy for Recurrent Cervical Cancer

Recurrent Cervical Carcinoma | Radiotherapy | Immune Checkpoint Inhibitors | Overall Survival | Anti-programmed Death-1 Antibody | Metastatic Cervical Carcinoma | Persistent Advanced Cervical Carcinoma | Objective Remission Rate | Progression-free Survival | Severe Adverse Events

China
Second Affiliated Hospital, School of Medicine,...

Recruiting

PD-1 Antibody Combined Neoadjuvant Chemotherapy for Ovarian Cancer

Ovarian Cancer | Neoadjuvant Chemotherapy | Anti-PD-1 | Neoadjuvant Immunotherapy

China
Changchun Zhuoyi Biological Co., Ltd

Completed

Observation on the Immune Persistence of People Aged 10-60 Years Old Immunized With Five Doses of Rabies Vaccine

Rabies | Antibody

China
Gladwin, Mark, MD

Terminated

Endothelial Injury and Development of Coronary Intimal Thickening After Heart Transplantation

Cardiac Allograft Vasculopathy | Antibody Mediated Rejection

United States
Maastricht Radiation Oncology

Completed

Immune Profiling After HDR in Local Relapsed Prostate Cancer (PRIMUS)

Prostate Cancer | PD-L1

Netherlands
Duke University

Recruiting

Genetic Risk Factors Associated With Antiphospholipid Antibody Syndrome (APS)

Antiphospholipid Syndrome

United States
Assistance Publique - Hôpitaux de Paris
URC-CIC Paris Descartes Necker Cochin

Not yet recruiting

Study of Salvage Therapy to Treat Patients With Granulomatosis With Polyangiitis (SATELITE)

Granulomatosis With Polyangiitis | Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis

France
Klemens Budde
Charite University, Berlin, Germany; Dr. med. univ. L. J. Lehner; ERA-EDTA; DESCARTES... and other collaborators

Not yet recruiting

European Transplant Registry of Senior Renal Transplant Recipients on Advagraf (SENIOR)

Infections | Quality of Life | Death | Cardiovascular Risk Factors | Graft Failure | Bone Disease | Post Transplant Diabetes Mellitus | Acute Rejection of Renal Transplant | HLA Antibody Production | Non-HLA Antibody Production
Changchun Zhuoyi Biological Co., Ltd

Enrolling by invitation

Prevention of Rabies With Four Doses of Rabies Vaccine

Rabies Human | Antibody

China
University of Florida
Hoffmann-La Roche

Completed

CoaguChek XS in Antiphospholipid Antibody Syndrome (APL) Patients

Antiphospholipid Antibody Syndrome

United States
National Institute of Allergy and Infectious Diseases...

Completed

Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB080-00-AB (VRC01LS), With Broad HIV-1 Neutralizing Activity, Administered Intravenously or Subcutaneously to Healthy Adults

Monoclonal Antibody, Human | HIV Antibodies | Neutralizing Antibody | Prevention of HIV Infection

United States
Stanley Jordan, MD

Active, not recruiting

Clazakizumab for Chronic and Active Antibody Mediated Rejection Post-Kidney Transplant

Kidney Transplant Rejection | Kidney Transplant; Complications | Antibody-mediated Rejection | Transplant Glomerulopathy | Transplant Glomerulopathy - Late Form | Transplant Glomerulopathy - Early Form

United States
Changchun Zhuoyi Biological Co., Ltd

Completed

Vaccine Prevention of Rabies Adopts 4-shot Immunization Method

Rabies Human | Antibody Titer

China
Amgen

Completed

A Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential of CCX168 With Concomitant Medications

Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis

United States
Thomas Jefferson University

Completed

Quantitative COVID-19 SARS-CoV-2 Antibody Pre and Post Cardiopulmonary Bypass

Laboratory Assessment SARS-CoV-2 Antibody Levels Before and After Surgery for Patients Requiring Cardiopulmonary Bypass

United States
Hospices Civils de Lyon

Completed

CASPR2 Encephalitis Initial Symptoms (iniCASPR2)

Paraneoplastic Syndromes | CASPR2-Antibody | Encephalitis Autoimmune

France
Chinese University of Hong Kong

Completed

Identifying Risks of COVID-19 Outbreaks in Work Settings and the Implications for Control Measures

Intention to Get SARS-CoV-2 Vaccination | Intention to Get SARS-CoV-2 Antibody Test

Hong Kong

Clinical Trials on PD-1 Antibody

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Sri Lanka

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations